financetom
Business
financetom
/
Business
/
Real Matters Swings to Q3 Net Loss As Revenues Fell
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Real Matters Swings to Q3 Net Loss As Revenues Fell
Jul 31, 2025 6:04 AM

08:44 AM EDT, 07/31/2025 (MT Newswires) -- Real Matters ( RLLMF ) , a network management services platform for the mortgage and insurance industries, on Thursday said that it swung to a loss as revenues fell in the third quarter.

The company's third-quarter net loss was reported at US$4.9 million or $0.07, compared to net income of US$1.7 million or $0.02 in the corresponding year-ago quarter, which the company attributed to an increase in net foreign exchange loss.

The company posted an adjusted net loss per diluted share of US$0.01 per share, compared to an adjusted net income per diluted share of US$0.02 per share in the year-ago quarter and consensus estimate compiled by FactSet of breakeven per share.

The company's net revenue for the quarter was US$11.9 million, down from $13.1 million in the year-ago quarter. Consensus estimate compiled by FactSet for revenue was US$13.2 million.

The company's consolidated revenue was US$45.4 million in the third-quarter, down 8% from US$49.5 million, as the company said that increased revenue in its U.S. Title segment was offset by lower year-over-year U.S. Appraisal revenue.

"We continued to launch new clients in the third quarter across all three of our segments and performed at the top of lender scorecards," said Real Matters ( RLLMF ) Chief Executive Officer, Brian Lang. "Subsequent to quarter end, we also went live with our second Tier 1 lender in U.S. Title and added a new top-15 lender in U.S. Appraisal. Overall, we remain on track with the execution of our strategy which is focused on growing market share and readying the business to scale up when mortgage market volumes normalize."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What's Going On With NIO Stock Wednesday?
What's Going On With NIO Stock Wednesday?
Oct 3, 2024
NIO, Inc. ( NIO ) shares along with other US listed Chinese stocks are trading lower Wednesday amid a possible selloff following Tuesday’s strength after China’s Central Bank announced a new stimulus package. The Details: The stimulus package provides for a cut to the reserve requirement ratio by 0.5 percentage points, drops the loan prime rate and deposit rates by...
US Steel says arbitration board rules in favor of Nippon Steel's $14.9 bln buyout deal
US Steel says arbitration board rules in favor of Nippon Steel's $14.9 bln buyout deal
Oct 3, 2024
Sept 25 (Reuters) - U.S. Steel said on Wednesday the board of arbitration, jointly selected by the steelmaker and the United Steelworkers union, has ruled in favor of Nippon Steel's ( NISTF ) $14.9 billion buyout deal. ...
Berenson Acquisition to Liquidate Following Termination of Custom Health Merger Deal
Berenson Acquisition to Liquidate Following Termination of Custom Health Merger Deal
Oct 3, 2024
10:59 AM EDT, 09/25/2024 (MT Newswires) -- Berenson Acquisition Corp. I ( BACA ) said Wednesday it will dissolve and liquidate following the termination of its merger agreement with Custom Health. The special purpose acquisition company said it will not complete the initial business combination by Sept. 30 as required, and thus will have to cease all operations. Its securities...
Biogen Sued by City of Baltimore Over Alleged Tecfidera Drug Pricing 'Scheme'
Biogen Sued by City of Baltimore Over Alleged Tecfidera Drug Pricing 'Scheme'
Oct 3, 2024
11:22 AM EDT, 09/25/2024 (MT Newswires) -- Biogen (BIIB) was sued by the city of Baltimore for allegedly engaging in an unlawful scheme to reduce competition from generic versions of its brand-name drug Tecfidera for multiple sclerosis. The class-action complaint alleges Biogen crafted a market-switch strategy by developing a next generation version of Tecfidera called Vumerity, which was different not...
Copyright 2023-2026 - www.financetom.com All Rights Reserved